Likewise, it is envisioned that induction of antigen editing with histone deacetylase (HDAC) inhibitors can be combined with immunotherapies for MM, including therapeutic antibodies or chimeric antigen receptor (CAR) T cells. This evidence concerns the gene HDAC9 and Miyoshi myopathy.